hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.
Company profile
Ticker
HEPA
Exchange
Website
CEO
Robert Foster
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ContraVir Pharmaceuticals, Inc.
SEC CIK
Corporate docs
Subsidiaries
ContraVir Research, Inc. • Hepion Research Corp. ...
HEPA stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Departure of Directors or Certain Officers
6 Mar 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
8-K
Departure of Directors or Certain Officers
7 Feb 24
8-K
Changes in Registrant's Certifying Accountant
3 Jan 24
8-K
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
7 Dec 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.28 mm | 19.28 mm | 19.28 mm | 19.28 mm | 19.28 mm | 19.28 mm |
Cash burn (monthly) | 3.75 mm | 3.32 mm | 3.55 mm | 3.99 mm | 3.75 mm | 3.06 mm |
Cash used (since last report) | 24.82 mm | 22.01 mm | 23.55 mm | 26.43 mm | 24.82 mm | 20.26 mm |
Cash remaining | -5.54 mm | -2.73 mm | -4.27 mm | -7.14 mm | -5.53 mm | -971.42 k |
Runway (months of cash) | -1.5 | -0.8 | -1.2 | -1.8 | -1.5 | -0.3 |
Institutional ownership, Q3 2023
55.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 4 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 4.00 bn |
Total shares | 2.40 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Hirschman Orin | 1.17 mm | $2.52 mm |
CVI Investments | 420.00 k | $920.00 k |
Armistice Capital | 397.61 k | $1.98 bn |
Vanguard | 165.51 k | $825.91 mm |
BLK Blackrock | 82.95 k | $413.94 mm |
Octagon Capital Advisors | 67.50 k | $336.83 mm |
Geode Capital Management | 34.91 k | $174.26 mm |
STT State Street | 15.68 k | $78.22 mm |
Susquehanna International | 14.64 k | $73.03 mm |
MS Morgan Stanley | 13.08 k | $65.25 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Feb 24 | Block Timothy M. | Stock Options Common Stock | Grant | Acquire A | No | No | 2.56 | 85,000 | 217.60 k | 99,562 |
19 Feb 24 | Jacob Gary S | Stock Options Common Stock | Grant | Acquire A | No | No | 2.56 | 85,000 | 217.60 k | 102,120 |
19 Feb 24 | Kaouthar Lbiati | Stock Options Common Stock | Grant | Acquire A | No | No | 2.56 | 85,000 | 217.60 k | 88,000 |
19 Feb 24 | Brancaccio John P | Stock Options Common Stock | Grant | Acquire A | No | No | 2.56 | 85,000 | 217.60 k | 99,563 |